HOME >> BIOLOGY >> NEWS
Potential diagnostic marker indicates effectiveness of anti-angiogenic drugs

CHICAGO -- If an anti-angiogenic drug is successfully starving a cancer patient's tumor to death, the number of endothelial cells circulating in the individual's bloodstream will decrease, thus providing a potential biomarker for gauging the medication's effectiveness, according to National Cancer Institute (NCI) research.

Previous studies have shown that the blood circulation of cancer patients has an abnormally high number of endothelial cells, which help construct blood vessels including those that feed the cancerous tumor.

"For a cancer to survive, grow and spread, a tumor needs to make more endothelial cells and construct new blood vessels to provide oxygen and other nutrients," said NCI scientist Haiqing Li, Ph.D., first author of the study.

"In addition to growing them directly from nearby blood vessels, tumors can also signal the body's bone marrow to boost the supply of endothelial cells in the blood circulation," Li added.

Results were presented at the first international meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

Anti-angiogenic drugs inhibit blood vessel development at the tumor by killing the endothelial cells lining tumor blood vessels and/or cutting off the supply of endothelial cells from bone marrow. These drugs are typically paired with chemotherapy agents. Unlike anti-angiogenic drugs, chemotherapy agents directly assault tumor cells, and a reliable therapeutic biomarker for evaluating these agents is whether there are fewer cells in the tumor, or more, or just the same amount as before the treatment. Some chemotherapy drugs, Li noted, also have the benefit of being toxic to endothelial cells, providing a possible second biomarker for those agents.

But biomarkers have yet to be defined for anti-angiogenic drugs. "Many anti-angiogenic drugs may encounter problems during clinical studies, because they can
'"/>

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
15-Sep-2006


Page: 1 2 3

Related biology news :

1. Potential genetic testing for substance abuse raises hope, concern
2. Potential for malaria transmission higher than previously thought
3. Potential new therapeutic target for asthma, allergies and cancer
4. Potential new treatment strategy for Alzheimers disease and other brain and spinal cord damage
5. Potential vaccine developed for deadly leishmaniasis disease
6. LIAI initiatives battle influenza; Potential bird flu treatment among their findings
7. Potential malaria drug target identified
8. Potentially harmful fluoride levels found in some instant teas
9. Potential new oncogene may be missing link in cancer-causing chain
10. Rutgers, Penn researchers capture research dollars to improve prostate cancer diagnostic methods
11. New Arizona alliance aims to boost technologies for medical diagnostics and human health

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2020)... , ... May 28, 2020 , ... ... that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) ... Meeting which will take place virtually on May 29th, 2020. Dr. Benedito Carneiro, ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... specializing in background and medical screening, announces the launch of a testing ... their workforce safe. The new service is provided by ClearStar’s Medical Information ...
(Date:5/21/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... May 20, 2020 , ... ... justice, and remove danger for all of us. The positions of these men and ... as from the defense for not following rules precisely. Officers have always had to ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now ... up to 200 million stem cells. Depending on the patient's condition, treatment may be ... US will die having some form of Alzheimers dementia, and the incidence continues to ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... insights, today announced that the launch of a new clinical diagnostics ... about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... develop a vaccine or drug treatment. In an effort to better understand the ... released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 ...
Breaking Biology Technology:
Cached News: